Profound Medical Corp. announced that, pursuant to the 2024 Final Rule published by the U.S. Centers for Medicare and Medicaid Services (?CMS?), use of HCPCS C code, C9734, previously established for the Hospital Outpatient Prospective Payment System (OPPS), has been extended for use in the Ambulatory Surgical Center (?ASC?) setting, and that MRI-Monitored Transurethral Ultrasound Ablation (?TULSA?) of prostate tissue, performed using Profound?s TULSA-PRO system, has been assigned device-intensive status. The ASC extension will go into effect on January 1, 2024.

C9734 was one of 11 HCPCS C codes that were added to the ASC Covered Procedure List, out of the 235 procedure recommendations CMS received. CMS determined that these 11 codes correspond to procedures that are frequently performed in outpatient settings and increasingly show lower risks of serious complications and inpatient admissions.